Hormonal
Mazindol, an anorexiant approved in Japan for short-term weight loss, significantly reduces body weight and total cholesterol compared to placebo in Japanese adults with obesity, but is associated with higher adverse event rates.
For Japanese adults with obesity, mazindol is an approved short-term treatment that significantly reduces body weight and total cholesterol compared to placebo. It acts by suppressing appetite. Patients should be aware of higher adverse event rates and the need for short-term use.
Mazindol also proved beneficial in reducing body weight and total cholesterol compared with placebo in Japan.
Why this rating
Based on a single older study (Kumahara et al.) with potential bias and limited generalizability to modern standards.
Source
Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment Comparison
Koutaro Yokote et al. · Advances in Therapy · 2024
DOI 10.1007/s12325-024-02941-7
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →